RenovoRx, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 9.89 million compared to USD 6.32 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 1.21 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.16 USD | -0.85% | -7.94% | -49.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.34% | 27.78M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.52% | 21.96B | |
-8.63% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022